Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Feb 26, 2009

Group Chooses Roche NimbleGen Microarrays for Neuromuscular Disorder Research

  • The NMD-Chip Consortium selected Roche NimbleGen microarrays for use in its activities related to neuromuscular disorders (NMDs). The group is working to develop a faster, more cost-effective diagnostic tool.

    Currently, it takes between two weeks to a year, according to the consortium, and the aim is to bring the time down to 72 hours to one week. The NMD-Chip Consortium comprises 13 European entities from eight countries.

    The consortium will use custom-designed NimbleGen Human CGH 12x135 K microarrays to locate gene- and exon-level rearrangements, deletions, or insertions associated with Duchenne/Becker muscular dystrophies, limb girdle muscular dystrophies, congenital muscular dystrophies, and hereditary motor-sensory neuropathies like Charcot-Marie-Tooth neuropathies. These high-throughput CGH will allow 12 research samples to be processed at the same time on a single array.

    In addition, the consortium will use customized NimbleGen Human Sequence Capture 385 K arrays to capture DNA fragments of all known genes implied in a given group of NMDs. This technology when coupled with high-throughput sequencing will provide quick evaluation of the gene variation underlying the NMDs being researched.

Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »